JAMA Oncology Author Interviews
JAMA Network
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
Episodes
Mentioned books
Nov 21, 2024 • 19min
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Oct 24, 2024 • 21min
Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Sep 5, 2024 • 17min
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
Interview with Eileen M. O'Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD. Related Content: Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
Aug 29, 2024 • 15min
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. Related Content: Identification of Immune Checkpoint Inhibitor–Induced Diabetes
Jul 18, 2024 • 19min
Neoadjuvant Exercise Therapy in Prostate Cancer
Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. Related Content: Neoadjuvant Exercise Therapy in Prostate Cancer
Jun 27, 2024 • 15min
Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals
Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. Related Content: Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals
Apr 18, 2024 • 20min
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD. Related Content: T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Mar 21, 2024 • 26min
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD. Related Content: Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
Feb 29, 2024 • 14min
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD. Related Content: Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Jan 4, 2024 • 18min
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD. Related Content: Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
